Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells

[1]  D. Weilguny,et al.  Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity , 2015, Clinical Cancer Research.

[2]  Hong Zhao,et al.  Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer , 2015, Breast Cancer Research.

[3]  R. Vyzula,et al.  Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. , 2015, Clinical breast cancer.

[4]  T. Nystul,et al.  EGFR signaling promotes self-renewal through the establishment of cell polarity in Drosophila follicle stem cells , 2014, eLife.

[5]  Stephen T C Wong,et al.  Chloroquine Eliminates Cancer Stem Cells Through Deregulation of Jak2 and DNMT1 , 2014, Stem cells.

[6]  R. Salgia,et al.  Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[7]  Dong Wang,et al.  Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts , 2013, Stem cell reports.

[8]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[9]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Xiang,et al.  Tumor‐Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox‐2 Signaling Pathway , 2013, Stem cells.

[11]  Jenny C. Chang,et al.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy , 2013, Breast Cancer Research.

[12]  G. Landberg,et al.  Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling , 2013, Breast Cancer Research.

[13]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[15]  L. Vahdat,et al.  Treatment of metastatic breast cancer: second line and beyond. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Katherine H. Rak Tkaczuk.  Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer , 2011, Breast cancer : basic and clinical research.

[17]  K. Tkaczuk.  Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer , 2011 .

[18]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[19]  Z. Fan,et al.  The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. , 2010, Cancer research.

[20]  Bing-he Xu,et al.  Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Frank,et al.  The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.

[22]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[23]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[24]  M. Clynes,et al.  Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  F. Lee,et al.  Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies , 2009, Molecular Cancer Therapeutics.

[26]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[27]  M. Ringnér,et al.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.

[28]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[29]  L. Vahdat.  Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. , 2008, The oncologist.

[30]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[31]  N. Anderson,et al.  Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. , 2007, Journal of the National Cancer Institute.

[32]  P. Dirks,et al.  Cancer stem cells: at the headwaters of tumor development. , 2007, Annual review of pathology.

[33]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[34]  C. Hudis.  Capecitabine in the Treatment of Advanced Breast Cancer , 2002 .

[35]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[36]  M. Noguchi,et al.  Sentinel lymphadenectomy in breast cancer: An alternative to routine axillary dissection , 1998, Breast cancer.

[37]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[38]  H. Bush,et al.  Breast Cancer Research , 1978, British Journal of Cancer.